Compare BYND & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | KRRO |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 187.9M |
| IPO Year | 2018 | 2019 |
| Metric | BYND | KRRO |
|---|---|---|
| Price | $11.51 | $10.34 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $0.83 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 950.3K | 151.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,496,000.00 | $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $0.40 | $5.20 |
| 52 Week High | $15.47 | $55.89 |
| Indicator | BYND | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 36.51 |
| Support Level | $0.65 | $10.40 |
| Resistance Level | $15.47 | $14.51 |
| Average True Range (ATR) | 0.77 | 1.29 |
| MACD | -0.36 | -0.36 |
| Stochastic Oscillator | 62.09 | 16.39 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.